Radiomics Analysis of PET and CT Components of PET/CT Imaging Integrated with Clinical Parameters: Application to Prognosis for Nasopharyngeal Carcinoma.


Journal

Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 24 1 2019
medline: 30 5 2020
entrez: 24 1 2019
Statut: ppublish

Résumé

To investigate the prognostic performance of radiomics features, as extracted from positron emission tomography (PET) and X-ray computed tomography (CT) components of baseline 2-deoxy-2-[ One hundred twenty-eight NPC patients (85 vs. 43 for training vs. validation), containing a subset of 86 patients with local-regional advanced stage, were enrolled. All patients underwent pretreatment PET/CT scans (mean follow-up time 24 ± 14 months). Three thousand two hundred seventy-six radiomics features extracted from PET or CT components and 13 clinical parameters were used to predict progression-free survival (PFS). Univariate analysis with Benjamini-Hochberg false discovery rate (FDR) correction was first used to screen significant features, and redundant features with Spearman's correlation > 0.8 were further eliminated. Then, seven multivariate models involving PET features and/or CT features and/or clinical parameters (denoted as clinical, PET, CT, clinical + PET, clinical + CT, PET + CT and clinical + PET + CT) were constructed by forward stepwise multivariate Cox regression. Model performance was evaluated by concordance index (C-index). Sixty patients encountered events (28 recurrences, 17 metastases, and 15 deaths). Six clinical parameters, 3 PET features, and 14 CT features in training cohort and 4 clinical parameters, 10 PET features, and 4 CT features in subset of local-regional advanced stage were significantly associated with PFS. Combining PET and/or CT features with clinical parameters showed equal or higher prognostic performance than models with PET or CT or clinical parameters alone (C-index 0.71-0.76 vs. 0.67-0.73 and 0.62-0.75 vs. 0.54-0.75 for training and validation cohorts, respectively), while the prognostic performance was significantly improved in local-regional advanced cohort (C-index 0.67-0.84 vs. 0.64-0.77, p value 0.001-0.059). Radiomics features extracted from the PET and CT components of baseline PET/CT images provide complementary prognostic information and improved outcome prediction for NPC patients compared with use of clinical parameters alone.

Identifiants

pubmed: 30671740
doi: 10.1007/s11307-018-01304-3
pii: 10.1007/s11307-018-01304-3
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

954-964

Références

Sci Rep. 2015 Jun 05;5:11044
pubmed: 26251068
Eur Radiol. 2017 Mar;27(3):1012-1020
pubmed: 27380902
Eur Radiol. 2018 Aug;28(8):3245-3254
pubmed: 29520429
AJNR Am J Neuroradiol. 2016 Sep;37(9):1706-12
pubmed: 27151750
Radiother Oncol. 2015 Sep;116(3):462-6
pubmed: 26163091
Eur J Cancer. 2013 Jul;49(10):2356-64
pubmed: 23541571
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1649-1660
pubmed: 29623375
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):567-580
pubmed: 27999896
IEEE Trans Med Imaging. 2009 Mar;28(3):374-83
pubmed: 19244009
Acta Oncol. 2017 Nov;56(11):1544-1553
pubmed: 28885084
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):618-25
pubmed: 19683403
Radiother Oncol. 2012 Feb;102(2):239-45
pubmed: 22098794
Comput Med Imaging Graph. 2002 Jan-Feb;26(1):33-42
pubmed: 11734372
Clin Cancer Res. 2013 Jul 1;19(13):3591-9
pubmed: 23659970
Eur Radiol. 2018 Jan;28(1):428-436
pubmed: 28770406
J Nucl Med. 2011 Mar;52(3):369-78
pubmed: 21321270
Mol Imaging Biol. 2016 Oct;18(5):788-95
pubmed: 26920355
Clin Cancer Res. 2016 Dec 1;22(23):5765-5771
pubmed: 27803067
Laryngoscope. 2017 Jan;127(1):E22-E28
pubmed: 27435352
Acta Oncol. 2015;54(9):1423-9
pubmed: 26264429
Clin Oncol (R Coll Radiol). 2013 Nov;25(11):639-46
pubmed: 23910226
Oral Oncol. 2017 Aug;71:150-155
pubmed: 28688683
Cancer. 2013 Mar 1;119(5):963-70
pubmed: 23065693
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):921-928
pubmed: 28807534
Acta Oncol. 2013 Oct;52(7):1391-7
pubmed: 24047337
AJR Am J Roentgenol. 2012 Jul;199(1):169-74
pubmed: 22733909
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):365-375
pubmed: 29046927
Expert Rev Precis Med Drug Dev. 2016;1(2):207-226
pubmed: 28042608
Nucl Med Commun. 2011 Nov;32(11):989-96
pubmed: 21862944
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):151-165
pubmed: 27271051
J Appl Clin Med Phys. 2017 Nov;18(6):32-48
pubmed: 28891217
Med Phys. 2017 Jul;44(7):3686-3694
pubmed: 28422299
Anticancer Drugs. 2010 Jun;21(5):471-7
pubmed: 20124988
Eur J Cancer. 2010 Jul;46(11):1967-78
pubmed: 20451372
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1090-1097
pubmed: 29246722
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Sci Rep. 2015 Aug 05;5:11075
pubmed: 26242464
Radiology. 2016 Sep;280(3):880-9
pubmed: 27326665
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
J Nucl Med. 2013 Oct;54(10):1703-9
pubmed: 24042030
Lancet. 2005 Jun 11-17;365(9476):2041-54
pubmed: 15950718
J Nucl Med. 2017 Mar;58(3):365-366
pubmed: 27811126
Radiother Oncol. 2015 Mar;114(3):345-50
pubmed: 25746350
Oncol Lett. 2017 Oct;14(4):5004-5012
pubmed: 29085513
Transl Cancer Res. 2016 Aug;5(4):371-382
pubmed: 30627523
Clin Cancer Res. 2017 Aug 1;23(15):4259-4269
pubmed: 28280088
Phys Med Biol. 2016 Jan 7;61(1):227-42
pubmed: 26639024
J Nucl Med. 2012 Jan;53(1):21-8
pubmed: 22213820
J Nucl Med. 2016 Mar;57(3):342-7
pubmed: 26541775
J Natl Cancer Inst. 2010 Aug 4;102(15):1188-98
pubmed: 20634482
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1477-85
pubmed: 26896298
Clin Cancer Res. 2015 Jan 15;21(2):249-57
pubmed: 25421725
Mol Imaging Biol. 2016 Dec;18(6):935-945
pubmed: 27324369
J Clin Oncol. 2015 Oct 10;33(29):3356-64
pubmed: 26351355
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):207-217
pubmed: 28944403
J Nucl Med. 2018 Aug;59(8):1321-1328
pubmed: 29301932

Auteurs

Wenbing Lv (W)

School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, 1023 Shatai Road, Guangzhou, 510515, Guangdong, China.

Qingyu Yuan (Q)

Nanfang PET Center, Nanfang Hospital, Southern Medical University, 1023 Shatai Road, Guangzhou, 510515, Guangdong, China.

Quanshi Wang (Q)

Nanfang PET Center, Nanfang Hospital, Southern Medical University, 1023 Shatai Road, Guangzhou, 510515, Guangdong, China. wangquanshiwl@126.com.

Jianhua Ma (J)

School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, 1023 Shatai Road, Guangzhou, 510515, Guangdong, China. jhma@smu.edu.cn.

Qianjin Feng (Q)

School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, 1023 Shatai Road, Guangzhou, 510515, Guangdong, China.

Wufan Chen (W)

School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, 1023 Shatai Road, Guangzhou, 510515, Guangdong, China.

Arman Rahmim (A)

Department of Radiology, Johns Hopkins University, 601 N. Caroline St., Baltimore, MD, 21287, USA.
Departments of Radiology and Physics & Astronomy, University of British Columbia, 6224 Agricultural Road, Vancouver, BC, V6T 1Z1, Canada.

Lijun Lu (L)

School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, 1023 Shatai Road, Guangzhou, 510515, Guangdong, China. ljlubme@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH